Whack-an-E. coli with the morbidostat
© BioMed Central Ltd. 2012
Received: 10 January 2012
Accepted: 24 January 2012
Published: 27 January 2012
Using a device termed the 'morbidostat', a recent study sheds new light on the determinism of genetic and phenotypic trajectories leading to high antibiotic resistance.
With the discovery of the first antibiotics in the 1940s, conventional wisdom held that the battle against pathogenic bacteria was won. However, shortly after the introduction of these new antibiotics, strains resistant to their action emerged. Today, resistance has been reported even against the latest line of combat embodied by newly developed antibiotics. At this point, it is clear that we do not fully understand the way resistance evolves. Paradoxically, pharmaceutical companies have shut down their basic research aimed at developing new antibiotics because of the low return on investment. In this bleak situation, gaining understanding of the way bacteria evolve antibiotic resistance is crucial.
After decades in which the study of evolutionary trajectories has advanced mainly theoretically, recent years have yielded several studies of in vitro evolution in controlled environments, inspired by the pioneering work of Lenski and colleagues . Controlled evolution of parallel bacterial populations in the laboratory has proved to be a tractable system for studying evolutionary trajectories in general [2, 3] and antibiotic resistance in particular [4, 5]. These studies define new challenges for the theoretical understanding of the way evolution proceeds.
Hammer versus mole
where μ is the rate of adaptation and Cmax is the maximal attainable resistance concentration. Cmax and μ characterize the evolutionary trajectory of an antibiotic. It is highly probable that apart from its dependence on the antibiotic chosen, μ also depends on parameters governing evolution, such as effective population size and mutation rate, whereas Cmax is characteristic mainly of the antibiotic itself. For example, trimethoprim and chloramphenicol have Cmax values that are three orders of magnitude higher than the initial half-maximal inhibitory concentration (IC50), whereas for doxycycline this parameter is only one order of magnitude higher. Once these parameters are known, they enable quantitative comparisons between different antibiotic regimes, for example different drug combinations. Indeed, the Kishony laboratory has demonstrated, in a series of clever studies, that resistance to drug combinations can work in a counterintuitive manner . Minimizing the rate of adaptation to a drug combination is an important clinical consideration, and the morbidostat provides a unique way to assess and compare adaptation rates. The universality of such parameters when characterizing a drug treatment remains to be determined: do they depend on local morbidostat settings or, instead, do they reveal some more inherent evolutionary factors?
The reproducibility of the resistance trajectories between parallel cultures seems to suggest that the underlying genetic trajectories are also similar. Making use of recent advances in whole genome sequencing (WGS), Kishony and colleagues characterized the end points of the parallel trajectories for all five replicates for each of three antibiotics. Whereas resistance mutations to trimethoprim were reproducibly located mainly in the target gene DHFR (encoding dihydrofolate reductase), diverse genetic alterations were found to underlie the strikingly similar trajectories for chloramphenicol (Figure 2). This notwithstanding, the majority of mutations observed under both chloramphenicol and doxycycline treatment converge mainly on one goal, namely decreasing the internal drug concentration by activating efflux, or decreasing influx, both under the control of the multiple drug resistance pathway . The authors analyzed further the reproducibility in the evolution of resistance to trimethoprim by Sanger sequencing the DHFR gene over time. This analysis revealed a typical accumulation order of the different single nucleotide mutations, indicating that the underlying genetic trajectory is reproducible.
Globally, the genes identified by WGS are not surprising: two-thirds of the genes identified are either direct targets of the antibiotics or genes involved in the multiple drug resistance pathway. The study identifies yedX, lpxM, manY and isrC as potential new players in the drug resistance game. However, the significance of the sequence data goes far beyond the mere identification of a handful of new genes. When considering the evolution of bacteria, one must bear in mind that, in the absence of recombination or sexual mating, selection forces are applied on the bacterial genome as a whole. A genome-wide perspective is therefore essential to the analysis of adaptive processes. WGS theoretically paints a complete picture of all the genomic differences between an evolved strain and the wild-type reference. Yet, it remains unclear if the entire evolutionary change is indeed unveiled by WGS, an issue that can be addressed by recreating the observed fitness of the evolved strains using allelic replacement . For example, it becomes clear that SNPs are not the sole contributors to genomic variation. Over the evolutionary process, the bacterial genome accumulates various types of chromosomal alterations, and their characterization is of uppermost importance for genome reconstruction. For example, gene duplication-amplification (GDA) events are among the most common types of mutations, occurring with a frequency of between 10-2 and 10-4 per cell . Previous studies have shown that bacteria can obtain resistance to different drugs, including chloramphenicol and trimethoprim, by duplicating various loci in their genome . A notable feature of GDAs is that they can be lost just as quickly as they appear, making this alteration unstable, especially when selection is removed. In the context of drug resistance, GDAs could grant bacteria transient resistance, thus allowing them to survive until a slower de novo adaptation appears in their genome, at which time the GDA could disappear. In the study of Kishony and colleagues, GDA was observed in only 4 out of the 19 strains that were sequenced; this is a low occurrence rate given earlier observations . This discrepancy could be interpreted as indicating that GDAs do not play a pivotal role in the scenario of dynamically sustained drug selection, or alternatively it could be due to their aforementioned fickle nature. Improvements in the current technologies and analyses will need to be applied to overcome the difficulties facing genome reconstruction. Furthermore, WGS of frozen intermediate evolving cultures could assist in capturing transient events such as GDAs. In future studies, the decreasing costs of paired-end sequencing and de novo assembly, along with the ever increasing quality and coverage of reads, should allow us to identify various types of chromosomal alterations (including GDAs, insertion elements, inversions and deletions), and also to fully characterize and localize these alterations within the genome.
In summary, the work of Kishony and colleagues represents an important advance in the way in vitro evolutionary experiments are conducted. Together with recent analyses of antibiotic resistance evolution under controlled conditions , their study paves the way forward for the development of new approaches that follow the evolution of antibiotic resistance in a reproducible way. Finally, experimental strategies similar to the morbidostat method could shed light on the evolution of drug resistance in cancer cells; this is another alarming example of rapid and aggressive asexual evolution under constant pressure, and which also has broad clinical consequences.
single nucleotide polymorphism
whole genome sequencing.
We thank E Toprak for providing the data shown in Figure 2.
- Lenski RE, Rose MR, Simpson SC, Tadler SC: Long-term experimental evolution in Escherichia coli. 1. Adaptation and divergence during 2,000 generations. Am Nat. 1991, 138: 1315-1341. 10.1086/285289.View Article
- Conrad TM, Joyce AR, Applebee MK, Barrett CL, Xie B, Gao Y, Palsson BO: Whole-genome resequencing of Escherichia coli K-12 MG1655 undergoing short-term laboratory evolution in lactate minimal media reveals flexible selection of adaptive mutations. Genome Biol. 2009, 10: R118-10.1186/gb-2009-10-10-r118.PubMedPubMed CentralView Article
- Barrick JE, Yu DS, Yoon SH, Jeong H, Oh TK, Schneider D, Lenski RE, Kim JF: Genome evolution and adaptation in a long-term experiment with Escherichia coli. Nature. 2009, 461: 1243-1247. 10.1038/nature08480.PubMedView Article
- Andersson DI, Hughes D: Gene amplification and adaptive evolution in bacteria. Annu Rev Genet. 2009, 43: 167-195. 10.1146/annurev-genet-102108-134805.PubMedView Article
- Lee HH, Molla MN, Cantor CR, Collins JJ: Bacterial charity work leads to population-wide resistance. Nature. 2010, 467: 82-113. 10.1038/nature09354.PubMedPubMed CentralView Article
- Toprak E, Veres A, Michel JB, Chait R, Hartl DL, Kishony R: Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat Genet. 2011, 44: 101-105. 10.1038/ng.1034.PubMedPubMed CentralView Article
- Chait R, Craney A, Kishony R: Antibiotic interactions that select against resistance. Nature. 2007, 446: 668-671. 10.1038/nature05685.PubMedView Article
- Ruiz C, Levy SB: Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli. Antimicrob Agents Chemother. 2010, 54: 2125-2134. 10.1128/AAC.01420-09.PubMedPubMed CentralView Article
- Conrad TM, Lewis NE, Palsson BO: Microbial laboratory evolution in the era of genome-scale science. Mol Syst Biol. 2011, 7: 509-PubMedPubMed CentralView Article
- Brochet M, Couve E, Zouine M, Poyart C, Glaser P: A naturally occurring gene amplification leading to sulfonamide and trimethoprim resistance in Streptococcus agalactiae. J Bacteriol. 2008, 190: 672-10.1128/JB.01357-07.PubMedPubMed CentralView Article